Aerska is developing delivery technologies intended to enable systemic delivery of RNA medicines to the brain to treat serious neurological diseases. The company is focused on improving selectivity of RNAi payload delivery and on approaches that could target multiple disease pathways simultaneously. Aerska announced an additional $10M investment from GHIC as part of its Series A, indicating ongoing Series A financing activity. The company positions the GHIC investment as a partnership to advance its platform toward clinical or translational goals. No public operating metrics or founding date were disclosed in the announcement.

Total raised

$70M

Funding rounds

3

Latest round

Series A

Latest activity

May 2026